Hiseco announced that its subsidiary Tibet Hiseco Pharmaceutical Co., Ltd. received the "Acceptance Notice" issued by the State Food and Drug Administration. The drug name is HSK45030 dispersible tablets, the dosage form is dispersible tablets, and the indication is intended for muscular dystrophy. HSK45030 is an oral, selective targeted small molecule inhibitor independently developed by the company. According to preclinical studies, HSK45030 can significantly and effectively reduce muscle damage caused by excessive contraction of sarcomeres and has demonstrated excellent anti-muscular atrophy effects in animal models.